Published in Medical Letter on the CDC and FDA, July 11th, 2004
The 1-year survival rate in patients treated with IRESSA on a compassionate basis was reported as 29.9%. This data set represents the largest reporting to date of clinical use of an agent in the epidermal growth factor receptor (EGFR) class.
The IRESSA EAP was initiated to allow access to the drug while it was pending U.S. Food and Drug Administration (FDA) approval. The program...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA